Technical Analysis for CRDF - Cardiff Oncology, Inc.

Grade Last Price % Change Price Change
grade D 20.75 1.17% 0.24
CRDF closed up 1.17 percent on Friday, December 4, 2020, on 1.13 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical CRDF trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 1.17%
Down 3 Days in a Row Weakness 1.17%
Slingshot Bullish Bullish Swing Setup -7.03%
NR7 Range Contraction -7.03%
Older End-of-Day Signals for CRDF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown 1 day ago
Down 5% 1 day ago
1.5x Volume Pace 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Medicine Cancer Clinical Medicine Pharmaceutical Drugs Solid Tumors Oncology Cancer Treatments Chemotherapy Acute Myeloid Leukemia Antineoplastic Drugs Leukemia Targeted Therapy Advanced Solid Tumors Solid Tumor Cancers Lymphomas Takeda Pharmaceutical Company Leukemias Metastatic Castration Resistant Prostate Cancer Metastatic Colorectal Cancer Chemotherapies Lestaurtinib

Is CRDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.5
52 Week Low 0.701
Average Volume 1,162,137
200-Day Moving Average 6.77
50-Day Moving Average 16.44
20-Day Moving Average 19.16
10-Day Moving Average 21.16
Average True Range 1.81
ADX 42.87
+DI 30.24
-DI 18.42
Chandelier Exit (Long, 3 ATRs ) 20.09
Chandelier Exit (Short, 3 ATRs ) 21.02
Upper Bollinger Band 24.01
Lower Bollinger Band 14.31
Percent B (%b) 0.66
BandWidth 50.64
MACD Line 1.78
MACD Signal Line 1.68
MACD Histogram 0.0968
Fundamentals Value
Market Cap 732.99 Million
Num Shares 35.3 Million
EPS -2.73
Price-to-Earnings (P/E) Ratio -7.61
Price-to-Sales 848.95
Price-to-Book 21.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.96
Resistance 3 (R3) 22.73 21.76 22.59
Resistance 2 (R2) 21.76 21.20 21.88 22.46
Resistance 1 (R1) 21.26 20.85 21.51 21.49 22.34
Pivot Point 20.29 20.29 20.42 20.41 20.29
Support 1 (S1) 19.79 19.73 20.04 20.02 19.16
Support 2 (S2) 18.82 19.38 18.94 19.04
Support 3 (S3) 18.32 18.82 18.91
Support 4 (S4) 18.55